IDENTIFICATION OF THE RAJI
CELL MEMBRANE-DERIVED Clq INHIBITOR
AS A RECEPTOR FOR HUMAN Clq
Purification and Immunochemical Characterization

BY BERHANE GHEBREHIWET, LOUI SILVESTRI,* AND C. McDEVITT

From the Department of Medicine, Division of Allergy, Rheumatology, and Clinical
Immunology, and the Department of Pathology, State University of New York, Stony Brook, New
York 11794; and the *Department of Medicine, the Diabetes Research and Training Center,
University of Alabama in Birmingham, Birmingham, Alabama 35294

Clq is a 410,000 mol wt glycoprotein that circulates in plasma at a concentra-
tion of 65-70 µg/ml and constitutes a subunit of the first component of comple-
ment, C1 (1). In plasma, C1 circulates as a calcium ion-dependent pentamolecular
complex consisting of one molecule of Clq, two molecules ofClr, and two
molecules ofCls, to give a structural formula, ClqClr2Cls2 (2). During activ-
ation of the classical pathway of complement, Clq, within the C1 macromole-
cule, functions as the recognition unit (3) by virtue of its ability to recognize and
bind to the Cn2 domain of IgG (4, 5) and Cn3 or Cn4 domains of IgM (6, 7). It
is a collagen-like molecule (1) with six flower-like globular heads that constitute
the binding sites for Ig (4). Each globular head contains the carboxyl-terminal
ends of three similar but distinct polypeptide chains (A, B, C) of ~20,000–
22,000 mol wt that occur six times in the molecule, forming six structural and
functional subunits (3, 8, 9). The amino-terminal regions of each chain are
collagen-like and associate to form a helical configuration that represents the
binding sites for Clr2Cls2 (9–10).

In addition to being a recognition unit of the classical pathway of complement,
Clq functions as a ligand for a number of cellular receptors (recently reviewed
in.11) such as B lymphocytes (12, 13), lymphoblastoid cells (14, 15), null cells,
monocytes, polymorphonuclear leukocytes (16, 17), fibroblasts (18), and platelets
(19, 20); and the binding of Clq to certain types of cells elicits some biological
functions. For instance, we have shown previously (15) that lymphocytes or
lymphoblastoid cells such as Raji cells are capable of lysing Clq-coated, chro-
nium-labeled chicken erythrocyte (Ecr)1 target cells. That the pre-killing, effector
cell–target cell contact is mediated by the effector cell Clq receptor (ClqR) was

1 Abbreviations used in this paper: ClqR, Clq receptor; CNBr, cyanogen bromide; DTT, dithio-
threitol; EA, antibody-sensitized sheep erythrocytes; EACA, epsilon-amino-caproic acid; Ech, chicken
eythrocytes; Eh, human erythrocytes; GVB, veronal-buffered saline containing 0.15 mM CaCl2, 0.5
mM MgCl2, and 0.1% gelatin; HBSS, Hanks' balanced salt solution; NHS, normal human serum;
NP-40, Nonidet P-40; PBS, phosphate-buffered saline; PEG, polyethylene glycol; PMSF, phenyl-
methylsulfonyl fluoride; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
demonstrated by pretreatment of the target cells with F(ab')2 anti-C1q, which abrogated the cytotoxic effect (15). Furthermore, monomeric C1q was reported to inhibit the collagen-dependent aggregation of platelets (19, 20) and the release of serotonin (21). The importance of C1qR was not fully appreciated, partly because, in normal serum, C1q occurs as a subunit of the C1 complex. The amount of available free C1q was therefore thought to be very small. However, C1qR assumed new significance after it was observed that CT-INA, the plasma inhibitor of activated C1, rapidly dissociates the activated C1r and C1s subunits from the C1 complex (22), thus leaving C1q bound to immune complexes.

In previous reports (23, 24), it was shown that a substance could be solubilized from membranes of lymphocytes or lymphoblastoid cells (Raji) that possesses the property of binding and precipitating free C1q, and hence was described as a C1q precipitin (23) or membrane-derived C1q inhibitor (M-C1qINH5) (24). In the present study, evidence is presented demonstrating that this membrane-derived inhibitor constitutes the cellular receptor for C1q.

Materials and Methods

Materials. The following materials were purchased: Nonidet P-40 (NP-40), lactoperoxidase, glutaraldehyde (Sigma Chemical Co., St. Louis, MO); Na125I and Bolton-Hunter reagent (New England Nuclear, Boston, MA); Ficoll-Hypaque (Pharmacia Fine Chemical, Piscataway, NJ), cyanogen bromide (CNBr) (Eastman Kodak Co., Rochester, NY), N,N-dimethylformamide (Aldrich Chemical Co., Milwaukee, WI), polyethylene glycol (PEG) (PEG 6000; Fisher Scientific Co., Pittsburgh, PA), and RPMI and other tissue culture reagents (Gibco Laboratories, Grand Island, NY).

Purified Proteins. Highly purified C1q was isolated according to a method previously described (25) and the protein concentration determined either by the method of Lowry et al. (26) or by measuring the optical density at 280 nM and using an extinction coefficient E1% of 6.8. The homogeneity of a representative preparation of C1q used in these studies is shown in Fig. 1.

Radioiodination of Proteins. All radiolabeled proteins were labeled with 125I by the Bolton-Hunter method as described (27) unless otherwise specified. Typically, 100 µg of isolated protein in 0.1 M sodium borate buffer (pH 8.5) were added to 100 µCi of Bolton-

![Image](attachment:image.png)

**Figure 1.** SDS-PAGE (7%) analysis of highly purified human C1q. Each gel contained 20 µg of protein. Unreduced human C1q consists of six A-B dimers and three C-C dimers that upon reduction yield equimolar amounts of three chains designated A, B, and C.
Hunter reagent and allowed to react for 30 min at 4°C. The reaction mixture was then dialyzed against phosphate-buffered saline (PBS), pH 7.0, at 4°C until the dialysate was free of 125I.

Preparation of Clq-Sepharose 4B. Highly purified Clq was coupled to Sepharose 4B according to the method described by March et al. (28). Briefly, 50 ml of packed Sepharose 4B was washed extensively with deionized water and resuspended in 50 ml of 5 mM potassium phosphate tribasic buffer, pH 12.5 and stirred in an ice bath kept in a fume hood for 15 min. Then 7 g of CNBr dissolved in 3.5 ml of N,N-dimethylformamide were quickly added and the mixture was stirred for 5 min. The Sepharose beads were then washed in a Buchner filter funnel in the fume hood with 2 liters of water followed by 2 liters of coupling buffer consisting of 8 g NaHCO₃, 29.2 g NaCl/l, pH 9.0. The CNBr-activated Sepharose was mixed in a wide-mouth, 250-ml plastic bottle with 50 ml of human Clq (2 mg/ml) that had been dialyzed against coupling buffer, and the mixture was left for 16 h at 4°C with continuous stirring, after which it was placed in a Buchner funnel and evacuated to dryness. The amount of protein coupled to the Sepharose was determined by assaying the protein content in the filtrate. The Clq-Sepharose was then washed with 1 liter of PBS, pH 7.0 and resuspended in 50 ml of 1 M glycine, pH 8.0 for 2 h at 22°C to block the unreacted sites on the Sepharose beads. The slurry was washed by filtration with 1 liter of 5 mM sodium phosphate buffer, pH 7.5, containing 0.5 mM EDTA, 150 mM NaCl, and 0.02% NaN₃, and poured into a 1.5 x 20 cm column. Before each use, the Clq-Sepharose column was tested for its activity by taking 0.5 ml of packed beads and incubating them with 0.2 ml of monospecific, polyclonal antiserum to Clq for 1 h at 4°C. After incubation the mixture was centrifuged (500 rpm, 5 min) and the remaining anti-Clq activity of the supernatant tested by Ouchterlony analysis, as shown in Fig. 2.

Lymphoblastoid Cell Line. The cell line, Raji, used in this study was taken from a continuous culture line propagated in RPMI containing 10% fetal calf serum and 1% antibiotic-antimycotic mixture and was originally derived from a patient with Burkitt's lymphoma (29, 30).

Purification of Clq Receptor. The purification of ClqR was essentially the same as that described earlier (24) with only minor modifications. Briefly, 3 x 10⁹ Raji cells were washed three times and resuspended in 100 ml of 5 mM sodium phosphate buffer, pH 7.5, containing 0.5 mM EDTA, 150 mM NaCl, 10 mM EACA, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Cell membranes were prepared by freeze-thawing (five times) at -80°C and centrifugation for 1 h at 30,000 g at 4°C. The pelleted membranes were then solubilized by suspension in 50 ml of the above buffer containing 1% NP-40 and stirred for 20 h at 4°C. The solubilized membrane proteins were freed from insoluble material by centrifugation at 30,000 g for 60 min at 0°C and the total protein concentration was determined to be 30 mg. After dialysis against 5 mM NaPO₄ buffer, pH 7.5, containing 0.5 mM EDTA, 20 mM NaCl, 10 mM EACA, 0.5 mM PMSF, and 0.1% NP-40, 10 mg of the dissolved membrane solution was applied to a 1.5 x 20 cm Clq-Sepharose 4B column that had been equilibrated with the same buffer. The column was then washed with 600 ml of the starting buffer and the specifically bound proteins eluted with a linear NaCl concentration gradient with 300 ml of starting buffer and 300 ml of same buffer containing 1 M NaCl. Fractions containing Clq-binding activity were deter-

![Figure 2](image-url) Depletion of anti-Clq activity on a Clq-Sepharose 4B column. A sample of a monospecific, polyvalent antibody to Clq was incubated with Clq-coated Sepharose. Depletion of anti-Clq was another means of showing that the Sepharose beads were coated with the Clq offered.
mined by single or double immunodiffusion techniques in a 0.8% agarose (sodium phosphate buffer, pH 7.2) containing 1.5% PEG 6000, using highly purified human C1q as described earlier (24, 31), and concentrated on an Amicon pressure filtration device with a Diaflow UM-10 ultrafiltration membrane (Amicon Corp., Danvers, MA). When the C1qR was used in a hemolytic assay, the detergent concentration was always reduced to ~0.01% by passage through a column of QAE-50 Sephadex as described (24).

**Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE)** Analysis of C1qR.

After radiolabeling with Bolton-Hunter reagent (27), the isolated C1qR was reduced and alkylated by boiling for 5 min in the presence of 0.1 M dithiothreitol (DTT) and 0.2 M iodoacetamide and was analyzed by application on a 1.5-mm thick, 5–10% acrylamide gradient containing slab gels, using the method of Laemmli (32). After electrophoresis, the gel was stained with Coomassie Blue, vacuum-dried, and analyzed by autoradiography.

**Ultracentrifugation Analyses.** Ultracentrifugation analysis of isolated C1qR was determined on a 5–40% sucrose-containing linear gradient in 5 mM NaPO₄ buffer containing 90 mM NaCl, 10 mM EACA, 0.5 mM EDTA, 0.5 mM PMSF, and 0.1% NP-40, pH 7.4. Centrifugation was carried out in a Beckman model L5-75B ultracentrifuge (Beckman Instruments, Inc., Fullerton, CA) using an SW65 rotor for 20 h at 50,000 rpm. C1q (11S), C3 (9.5S), albumin (4.6S), and cytochrome c (1.7S) were used as markers.

In another set of experiments, an equilibrium density gradient ultracentrifugation was run in the following manner. First, the isolated C1qR was dialyzed overnight at 4°C against distilled water and then lyophilized. The dried residue was then dissolved in 8 ml of a solution comprised of 4 M guanidinium chloride, 0.05 M sodium acetate, pH 5.8, N-ethyl malimide, 0.1 M EDTA, 0.1 M EACA, and 0.005 M benzamidine, that contained cesium chloride to a density of 1.5 g/ml. The solution was centrifuged at 12°C for 72 h at 100,000 rpm in a Beckman ultracentrifuge using a swing-out rotor (SW60). The tubes were then frozen in liquid nitrogen and cut into two fractions: the bottom 2/5 and the bottom 3/5 by volume. The fractions were then dialyzed against 0.2 M sodium acetate, pH 5.8 and then against distilled water at 4°C. Finally, the material was lyophilized and then dissolved in 1.0 ml of distilled water. Protein and uronate were determined on an autoanalyzer (Techicon Instruments Corp., Tarrytown, NY).

**Amino Acid Analysis.** Amino acid analysis was performed with an amino acid analyzer (model 121M; Beckman Instruments, Spinco Division, Palo Alto, CA) equipped with an automatic sample injector and a model System AA automatic digital integrator. The sample was hydrolyzed in 6 N HCl for 20 h at 110°C in evacuated and sealed Pyrex tubes. ~25 nmol of hydrolyzed protein were applied to each column and the amino acid concentration was determined by comparison with a standard mixture of amino acids (100 nmol/ml).

**Effect of Chondroitinase ABC on C1qR.** To determine the effect of chondroitinase ABC, 0.1 µg purified [125I]C1qR was dissolved in 0.1 µl of Tris-HCl, pH 8.0, and incubated with buffer alone or with 0.1 U of enzyme as described previously (31) for 12 h at 37°C. Then the sample was dialyzed against buffer containing 0.14 M Na₂SO₄, 0.01 cacodylic acid, and 0.1% NP-40. The chondroitinase-digested sample and the control sample were sequentially applied to a column of Sepharose CL-6B (0.5 × 120 cm; matrix, 108 cm) equilibrated with same buffer together with 250 µg of bovine nasal cartilage proteoglycan A1D1 (V₅ marker, 2.2 × 10⁶ mol wt) and 20 µg glucuronolactone (V₅ marker, 176 mol wt) and eluted with the same buffer at a flow rate of 5 ml/h. Fractions were analyzed by Ouchterlony using isolated C1q and by the carbazole method of uronic acid determination (33).

**Inhibition of EC1q Rosettes by C1qR or Monoclonal Antibody to C1qR.** The ability of C1qR to inhibit C1q-dependent rosette formation was determined by a previously described rosette assay (34, 35) and consists of the following steps. First, human erythrocytes (E₅) were treated with 100 vol of 2% glutaraldehyde in 0.15 M PBS, pH 7.4, at 4°C for 16 h. The cells were washed with Hanks' balanced salt solution (HBSS) and further incubated with 10 vol of HBSS containing 10 mg/ml L-lysine for 30 min at 37°C, after which the cells were washed and resuspended in HBSS at 1 × 10⁹/ml. Then 5 × 10⁶ cells
in 1 ml HBSS were incubated with 200 μg Clq and a tracer amount (1 μg) of ^125I-Clq (8 × 10^5 cpm/μg). The excess unbound Clq was removed by centrifugation in HBSS. Rosette formation was then assayed by incubating 1.5 × 10^7 Eta Clq with 5 × 10^5 Raji cells in a total volume of 0.4 ml HBSS for 5 min at 37°C, centrifuging for 5 min at 600 rpm, and further incubation for 60 min at 4°C. To determine the inhibitory effect of isolated ClqR, the Raji cells were either pretreated with 5 μg/ml F(ab')2 or the reaction mixture was incubated in the presence of 5 μg ClqR. The percent rosettes formed was determined by counting at least 100 lymphocytes in a microscope (Microstar; American Optical Scientific Instruments, Buffalo, NY).

Clq-dependent Cytotoxicity Assay. 51Chromium-labeled, Clq-coated chicken erythrocyte target cells (^51Cr-EC) were prepared as described earlier (15). The inhibitory effect of ClqR was tested by preincubating 10 μg ClqR with 8 × 10^4 ^51Cr-EC and leaving the excess unbound ClqR in the reaction mixture, which contained, in addition, 2 × 10^5 Raji cells in a total volume of 0.4 ml of RPMI containing 0.4 human serum albumin, 2 mM L-glutamine, and 1% antibiotic-antimyocytic mixture (penicillin 10,000 U/ml, fungizone 25 μg/ml, streptomycin 10,000 mcg/ml). Incubation was carried out at 37°C in a CO2 incubator for 20 h. After incubation, the reaction mixture was centrifuged for 10 min at 1,000 rpm, the radioactivity of both pellet and supernatant determined, and cell damage expressed as the percentage of the total radioactivity released from the cell into the supernatant.

Effect of Isolated ClqR on Clq Hemolytic Function. There is evidence in the literature indicating that the Clq receptor reacts with the collagen-like region of the molecule (16, 24). Since this region also constitutes the site to which C1r and C1s bind, an experiment was performed to see if the isolated molecule could inhibit the hemolytic activity of C1 in serum. This was determined by incubating 5 μg/ml of purified ClqR (which had been repurified on a QAE-Sephadex column to reduce the detergent concentration) with or without 50 ng of Clq for 60 min at 37°C, followed by an additional 60 min incubation in the presence of 10 μl of C1q-depleted serum (containing 20 mM CaCl2 and antibody-sensitized sheep erythrocytes (EA) (5 × 10^9/ml) in a total volume of 0.5 ml GVB (veronal-buffered saline containing 0.15 mM CaCl2, 0.5 mM MgCl2, and 0.1% gelatin) (24). After incubation, the cells were centrifuged and the amount of hemoglobin released into the supernatants was determined spectrophotometrically at 700 nm. The inhibitory effect of the isolated substance was expressed as the percent inhibition of Clq hemolytic activity.

Results

Purification of ClqR by Affinity Chromatography. When a total of 10 mg of unlabeled and tracer amount (1 × 10^6 cpm/μg) of surface-labeled, NP-40-solubilized Raji cell membranes were chromatographed on a Clq-Sepharose 4B column and bound proteins eluted with a linear NaCl concentration gradient, two discrete, Clq-reactive peaks eluted at approximately 22 and 30 mmho/cm, respectively (Fig. 3). This seems to suggest that Raji cells possess two species of receptors with different affinities or charge heterogeneity. The two peaks were then separately pooled, concentrated, and designated arbitrarily as Clq receptor I and II (ClqRI and -II). From the tracer amount of radiolabeled protein incorporated, it was determined that the two Clq-reactive proteins represent ~7% of the total labeled Raji cell membrane proteins.

Immunodiffusion Analysis of Isolated ClqR. Equal concentrations of the pooled and concentrated peaks, ClqRI and ClqRII, were tested for their ability to bind and precipitate Clq using double (Fig. 4A) and single (Fig. 4B) immunodiffusion techniques. Both pools were found to be reactive, although the precipitation ring obtained by ClqRII (Fig. 4B) was apparently stronger than that for ClqRI, probably due to the disparity in concentration, since ClqRII was found to
contain at least two other protein bands (see below). Furthermore, CIqR was found to react with normal human serum (NHS) that contains EDTA but not NHS alone, indicating that under physiologic conditions where CIq is in complex with C1r2 and C1s2, the receptor does not bind to CIq in NHS.

**SDS-PAGE Analysis of CIqR.** Both CIqRI and CIqRII were radiolabeled with 125I and analyzed on a 10% SDS gels. As shown in Fig. 5, both CIqR preparations contained a major band (80–90 kD) that, under reducing conditions, resulted in a single, 60–70 kD band. However, while CIqRII was relatively homogeneous, CIqRI was found to contain at least two distinctly visible bands that together represented ~50% of the preparation.

It is also of interest that the CIqR molecule has a much more pronounced 125I band upon reduction than without reduction, indicating that the protein moiety might exist as a polymeric structure of disulfide-bonded 70,000 mol wt chains. Furthermore, some visible bands were observed at the top of the gel, and two or three protein bands were visible that did not label with 125I.

**Ultracentrifugation Analysis.** Sucrose density ultracentrifugation analysis revealed that the CIqR sediments at ~4.2 S; the results of one such experiment is shown in Fig. 6. In addition, equilibrium density gradient ultracentrifugation showed that the isolated receptor could be separated into a protein-rich, low density fraction and a carbohydrate-rich, high density fraction (Table I). The large hydrodynamic size, coupled with the high buoyant density and uronic acid content, suggests that a proteoglycan is a constituent of the complex.

**Amino Acid Analysis.** The results of amino acid analysis data are represented in Table II. One of the striking features is that CIqR is rich in glycine, with glutamic acid and aspartic acid following closely behind, which explains its acidic
FIGURE 4. Immunodiffusion analyses of ClqR. Isolated receptor pools were analyzed by double (A) and single (B) immunodiffusion techniques. Both plates contained 0.8% agarose in PBS, pH 7.4, 1.5% PEG, and 0.02% NaN₃. The agarose in plate B contained, in addition, 25 μg/ml of purified Clq. ClqRII precipitated Clq in NHS containing EDTA (NHS-E) but not in NHS.

nature. The hexosamine ratio, or the ratio of galactosamine to glucosamine, was found to be 3.2. Furthermore, the uronic acid content of a typical ClqR preparation was found to be 23%, while galactosamine content was 21%.

Digestion of ClqR with Chondroitinase ABC. Previous studies postulated that the plasma-derived Clq inhibitor, which was identified as a chondroitin 4-sulfate proteoglycan (31), and the lymphocyte membrane-derived Clq inhibitor (ClqR), could be similar or identical. To assess this issue, an experiment was designed in which the ClqR was incubated with either buffer or chondroitinase ABC, as described in Materials and Methods. Both materials were then applied to a CL-6B column (0.5 x 120 cm; matrix height, 105 cm). After elution, it was found that the treated and untreated ClqR chromatographed in the same region, with a Kᵥ of 0.45 (Fig. 7), indicating that ClqR is not digestable with chondroitinase. Furthermore, chondroitinase-digested ClqR did not lose its ability to precipitate Clq as assessed by a double radial immunodiffusion analysis, as described.

Inhibition of Clq-dependent Biological Functions by ClqR. The ability of isolated ClqR to inhibit Clq-dependent rosette formation was tested by preincubating glutaraldehyde-treated, Clq-coated E₅ with or without 5 μg/ml of the receptor and then with either peripheral blood lymphocytes that had been purified by centrifugation on Ficoll-Hypaque (36) or Raji cells for 60 min at 4°C. As shown in Table III, 5 μg/ml of ClqR was able to inhibit rosette formation. Furthermore,
FIGURE 5. SDS-PAGE gel analysis of Clq-Sepharose pools. The pooled fractions in Fig. 3 were concentrated and radiolabeled before further purification. The specific activity was $7.7 \times 10^5$ and $5.1 \times 10^5$ cpm/µg for pool I (ClqRI) and pool II (ClqRII), respectively. $\sim 5 \times 10^4$ cpm ($\sim 7$ µg) of each sample was applied to a Laemmli slab gel (10%) in the absence (1 and 3) or presence (2 and 4) of 0.1 M DTT. After electrophoresis the gel was stained with Coomassie Blue, vacuum-dried, and exposed in a Dupont Cronex cassette with Lightning Plus screens for 24 h at −80°C before autoradiographic analysis.

both the Clq-dependent cellular cytotoxicity (Table IV) and hemolytic functions (Table V) were found to be inhibited by ClqR.

**Discussion**

In previous reports (23, 24) we isolated a lymphocyte membrane–associated Clq precipitin (23) or M-Clq inhibitor (24) and demonstrated that it was capable of inhibiting some of the Clq-dependent biological functions. The questions that arose from these studies were: (a) What is the exact chemical nature of the membrane-derived Clq inhibitor? (b) What is its relationship to the plasma Clq inhibitor? and (c) Is the Clq inhibitor identical to the Clq receptor on lymphocytes? To answer these questions and further characterize the chemical, as well as the functional nature, the membrane-associated inhibitor was isolated to homogeneity using a Clq–Sepharose 4B affinity column as described earlier (23). The present results clearly demonstrate that the isolated Clq inhibitor constitutes the cellular receptor for Clq and that it may exist as two distinct populations of receptors possessing different affinities for the Clq molecule.
This conclusion is derived from the observations that when the detergent-solubilized membrane proteins were applied to the Clq-Sepharose 4B column, washed exhaustively, and the adsorbed materials eluted, two discrete peaks eluting at different ionic strengths (22 and 30 mmho/cm, respectively) were obtained. Both species had similar properties since both were capable of binding
and precipitating free C1q, although the concentration of C1qRI (after further purification) required to precipitate the same amount of C1q was one-half that of pool II. However, the conclusion that two distinct cell receptor populations might exist should await binding studies to determine their affinity constants. C1q possesses two binding sites for certain types of mucopolysaccharides such as low molecular weight heparin (37); the high affinity-binding site was shown to be the collagenous region of the molecule. That the C1q inhibitor is a cellular receptor for C1q (C1qR) is inferred from the following lines of evidences. (a) When the isolated material or C1qR was preincubated with C1q-bearing, glutaraldehyde-treated E₅, no rosette formation was obtained upon subsequent incubation with lymphocytes or Raji cells. (b) C1q-coated, §Cr-labeled chicken erythrocyte target cells were prevented from lysis by Raji cells when the target cells were first preincubated with the C1qR. That this complement-mediated cellular cytotoxicity (CDCC) is mediated by the effector cell–C1q receptor has been previously documented (15). (c) C1qR binds to free C1q and this C1qR-bound C1q was unable to reassemble and form a hemolytically active C1 in the presence of C1q-depleted serum and 20 mM Ca++. (d) In addition, other experiments have shown that binding of $^{125}$I-C1q to Raji cells was abrogated in the presence of C1qR, indicating that the isolated receptor could compete for
the binding of C1q. (e) Furthermore, murine F(ab')2 monoclonal antibody to C1qR was found to inhibit $^{125}$I-C1q binding to Raji cells.2

The C1q molecule is collagen-like with six globular heads that are the binding sites for Ig. The collagenous tail of the molecule is considered to be the site where C1r and C1s bind in plasma. The collagenous region of the molecule constitutes the site through which C1q binds to receptors (14–17). Our finding that C1qR was unable to precipitate C1q in serum seems to confirm these findings.

The results obtained from equilibrium gradient ultracentrifugation indicate

---

2 Ghebrehiwet, B. Murine monoclonal antibody that interacts with human C1q receptor. Manuscript submitted for publication.
TABLE IV

Inhibition of C1q-dependent Cytotoxicity by C1qR

| Reaction mixture | Percent 51Cr release* |
|------------------|-----------------------|
| Raji + 51Cr-Ec   | 5                     |
| Raji + 51Cr-Ec, Clq | 74                   |
| Raji + (C1qR + 51Cr-Ec, Clq) | 10                  |

* 1 x 10⁷ 51Cr-labeled, C1q-coated Ec target cells were incubated with 5 x 10⁵ Raji cells in the presence or absence of 5 µg/ml C1qR in a total volume of 0.3 ml RPMI plus 5% FCS for 20 h at 37°C in an atmosphere of 95% air and 5% CO₂. After incubation, cells were centrifuged and the radioactivity of both pellet and supernatant determined. Cell damage is expressed as percent of total radioactivity released from the cells into the supernatant.

TABLE V

Reduction of C1q Hemolytic Activity by C1qR

| Reaction mixture | Percent hemolysis | Percent inhibition |
|------------------|------------------|--------------------|
| (C1q + GVB) + C1qD + EA* | 89               | --                 |
| (C1q + C1qR) + C1qD + EA | 40               | 55*                |

* Highly purified C1q was incubated either with GVB or 5 µg/ml C1qR before addition to C1q-depleted serum (C1qD) in the presence of 20 mM CaCl₂. Hemolysis was expressed as percent of NHS-induced hemoglobin release.

The biological significance of the receptor cannot be determined from these studies. It is clear, however, that the receptor does bind only to free C1q. Upon activation of the classical pathway of complement by immune complexes, CT-INA, the plasma inhibitor of activated C1, binds to C1r and C1s to form an irreversible complex, and thus readily dissociates them from the C1q molecule. Under these conditions, the collagenous tail of the C1q molecule becomes exposed and possibly available to bind to cell surface receptors on monocytes, lymphocytes, or polymorphonuclear cells (PMN), though this type of C1q is believed to be conformationally changed (38). Whether binding of a C1q-
containing immune complex to a phagocytic cell Clq receptor represents one mechanism of immune clearance remains to be investigated. The binding of free Clq to cells possessing receptors for Clq promotes biological functions, as is apparent from studies which found that $^{51}$Cr-labeled, Clq-E$_c$ could be lysed by Raji cells as well as by lymphoblastoid cells in the absence of anti-target cell antibody (15). This Clq-mediated cellular cytotoxicity could be inhibited if the Clq-coated target cells were first pretreated with ClqR (15). In addition, Clq has been reported (18-20) to inhibit collagen-dependent platelet aggregation and serotonin release. Whether this inhibition is mediated by a specific platelet receptor for Clq or if the platelet recognizes the collagen portion of the Clq through a specific receptor for collagen is not clear. The Clq receptor isolated from Raji cells is similar if not identical to the receptor on PMN or platelets, as has been confirmed through immunoprecipitation studies using Clq-coated Sepharose beads and murine monoclonal antibody raised to the receptor (manuscript in preparation). More work is needed to determine the precise function of cellular Clq receptor.

Summary

We have shown previously that an activity which is capable of precipitating purified Clq and inhibiting some of the Clq-dependent biologic reactions could be solubilized from the membranes of both normal human peripheral B lymphocytes and a B cell-derived lymphoblastoid cell line (Raji), both of which are known to possess receptors for human Clq. In this report we present evidence that this membrane-associated Clq inhibitor is a chondroitinase-insensitive macromolecule and is the receptor for human Clq. The receptor was solubilized from membranes of Raji cells with Nonidet P-40 and purified to homogeneity using Clq-Sepharose 4B affinity chromatography. Equilibrium density gradient centrifugation analysis revealed that the complex could be resolved into a protein-rich, low density fraction and a carbohydrate-rich, high density fraction. The large hydrodynamic size, coupled with the high buoyant density, suggests that a proteoglycan is a constituent of the complex and indicates that the receptor might be a macromolecular complex of a proteoglycan portion noncovalently linked to a 60-70 kD glycoprotein. The glycoprotein moiety, in turn, consists of two or more identical (70,000 mol wt) polypeptide chains held together by disulfide bonds and constitutes the Clq receptor (ClqR). Sucrose density ultracentrifugation analysis showed that the isolated receptor sediments with an apparent rate of 4.2 S. Immunochemical analyses demonstrated that a typical preparation of the ClqR complex consists of $\sim 23\%$ uronic acid and $\sim 21\%$ galactosamine with a galactosamine-to-glucosamine ratio of 3.2. Binding of Clq to the receptor was found to be optimal at low ionic strength and neutral or near-neutral pH (7-7.4). The isolated receptor was found to inhibit Clq hemolytic function, abrogate Clq-dependent rosette formation, and block the Clq-dependent, cell-mediated cytotoxicity, all of which are activities mediated by the receptor.

We wish to thank Miss Austin Chen for excellent technical assistance and Mrs. Karen Abramowski for preparing the manuscript.
Received for publication 2 July 1984.

References

1. Calcott, M. A., and H. J. Müller-Eberhard. 1972. C1q protein of human complement. Biochemistry. 11:3443.
2. Porter, R. R. 1981. The proteolytic enzymes of the complement system. Methods Enzymol. 80:3.
3. Müller-Eberhard, H. J. 1980. Complement: molecular mechanisms, regulation and biologic function. In Molecular Basis of Biological Degradative Processes. R. Berlin, H. Hermann, I. Lepow, and J. Tanzer, editors. Academic Press, Inc., New York. 65.
4. Shelton, E., K. Yonemasa, and R. M. Stroud. 1972. Ultrastructure of the human complement component C1q. Proc. Natl. Acad. Sci. USA. 69:65.
5. Kehoe, J. M., M. Fangerau. 1969. Immunoglobulin peptide with complement-fixing activity. Nature (Lond.). 224:1212.
6. Hurst, M. M., J. E. Volanakis, R. B. Hester, R. M. Stroud, and J. C. Bennett. 1974. The structural basis for binding of complement by immunoglobulin M. J. Exp. Med. 140:1117.
7. Plaut, A. G., S. Cohen, and T. B. Tomasi. 1972. Immunoglobulin M: fixation of human complement by the Fc fragment. Science (Wash. DC). 176:55.
8. Porter, R. R. 1977. Structure and activation of the early components of complement. Fed. Proc. 36:2191.
9. Reid, K. B. M., R. B. Sim, and A. P. Faiers. 1977. Inhibition of the reconstitution of the hemolytic activity of the first component of human complement by a pepsin-derived fragment of subcomponent C1q. Biochem. J. 161:239.
10. Reid, K. B. M., J. Gagnon, and J. Frampton. 1982. Completion of the amino acid sequences of the A and B chains subcomponent C1q of the first component of human complement. Biochem. J. 203:559.
11. Schreiber, R. D. 1984. The chemistry and biology of complement receptors: Springer Semin. Immunopathol. In press.
12. Dickler, H. B., and H. G. Kunkel. 1972. Interaction of aggregated gamma-globulin with B lymphocytes. J. Exp. Med. 136:191.
13. Sundqvist, K. G., S. E. Svehag, and R. T. Thorstenson. 1974. Dynamic aspects of the interaction between antibodies and complement at the cell surface. Scand. J. Immunol. 3:237.
14. Sobel, A. T., and V. A. Bokisch. 1975. Receptor for C1q on peripheral human lymphocytes and human lymphoblastoid cells. Fed. Proc. 34:965.
15. Ghebrehiwet, B., and H. J. Müller-Eberhard. 1978. Lysis of C1q-coated chicken erythrocytes by human lymphoblastoid cell lines. J. Immunol. 120:27.
16. Tenner, A. J., and N. R. Cooper. 1980. Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J. Immunol. 125:1658.
17. Tenner, A. J., and N. R. Cooper. 1982. Purification and partial characterization of a human polymorphonuclear leukocyte C1q receptor. Fed. Proc. 41:965.
18. Bordin, S., W. P. Kolb, and R. C. Page. 1985. C1q receptors on cultured human gingival fibroblasts: analysis of binding properties. J. Immunol. 130:1871.
19. Cazenave, J. P., S. N. Assimeh, R. H. Painter, M. A. Packham, and J. F. Mustard. 1976. C1q inhibition of the interaction of collagen with human platelets. J. Immunol. 116:162.
20. Suba, E. A., and G. Csako. 1976. C1q (C1) receptor on human platelets: inhibition of collagen-induced platelet aggregation by C1q (C1) molecules. J. Immunol. 117:304.
21. Wautier, J. L., K. B. M. Reid, Y. Legrand, and J. P. Caen. 1980. Region of the C1q molecule involved in the interaction between platelets and subcomponent C1q of the first component of complement. Mol. Immunol. 17:1399.
22. Sim, R. B., G. J. Arlaud, and M. G. Colomb. 1979. C5 inhibitor-dependent dissocia-
tion of human complement component C1 bound to immune complexes. Biochem. J. 179:449.
23. Ghebrehiwet, B. 1981. C1q-inhibitor (C1qINH): functional properties and possible relationship to a lymphocyte membrane-associated C1q precipitin. J. Immunol. 126:1837.
24. Ghebrehiwet, B., and M. Hamburger. 1982. Purification and partial characterization of a C1q inhibitor from the membranes of human peripheral blood lymphocytes. J. Immunol. 129:157.
25. Yonemasu, K., and R. M. Stroud. 1971. C1q: rapid purification method for preparation of monospecific antisera and for biochemical studies. J. Immunol. 106:304.
26. Lowry, O. H., H. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265.
27. Bolton, A. E., and W. M. Hunter. 1973. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay. Biochem. J. 138:259.
28. March, S. C., I. Parish, and P. Cuatrecasas. 1974. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal. Biochem. 60:149.
29. Pulvertaft, R. J. V. 1965. A study of malignant tumors in Nigeria by short-term tissue culture. J. Clin. Pathol. 18:261.
30. Klein, E., G. Klein, J. S. Nadkarni, J. J. Nadkarni, H. Wizzell, and P. Clifford. 1968. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and derived culture lines. Cancer Res. 28:1300.
31. Silvestri, L., J. R. Baker, L. Roden, and R. M. Stroud. 1981. The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J. Biol. Chem. 256:7383.
32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680.
33. Ford, J. D., and J. R. Baker. 1978. Procedure for the automated analysis of proteoglycans and glycosaminoglycans. Anal. Biochem. 84:539.
34. Hughes-Jones, N. C. 1977. Functional affinity constants of the reaction between 125I-labelled C1q and C1q binders and their use in the measurement of plasma C1q concentrations. Immunology 32:191.
35. Gabay, Y., H. Perlmann, and A. T. Sobel. 1979. A rosette assay for the determination of C1q-receptor-bearing cells. Eur. J. Immunol. 9:797.
36. Boyum, A. 1968. Separation of lymphocytes and erythrocytes by centrifugation. Scand. J. Clin. Lab. Invest. 97:77.
37. Almeda, S., R. D. Rosenberg, and D. H. Bing. 1983. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J. Biol. Chem. 258:785.
38. Golan, M., R. Burger, and M. Loos. 1982. Detection of conformational changes within the C1q molecule with monoclonal anti-C1q antibodies. Mol. Immunol. 19:1371.